Pfizer Reports Q2 Earnings for FY2023 on August 9th
August 22, 2023
🌥️Earnings Overview
PFIZER INC ($NYSE:PFE) reported their financial results for the second quarter of FY2023, which ended on June 30 2023, on August 9 2023. Total revenue was USD 12.7 billion, unchanged from the same period in the previous year. Net income remained the same as the year before at USD 2.3 billion.
Share Price
On Wednesday, Pfizer Inc. reported their second quarter earnings for Fiscal Year 2023, with their stock opening at $35.6 and closing at $35.8, up 0.6% from its previous closing price of $35.6. The company’s top earners were Lyrica, Ibrance, Eliquis, and Chantix.
Additionally, sales of vaccines and consumer healthcare products also increased significantly, with vaccines contributing $2.3 billion in revenue and consumer healthcare products contributing $2 billion in revenue. The positive results of the second quarter demonstrate Pfizer Inc.’s commitment to innovation and efficiency, as the company was able to continue to drive growth despite the numerous challenges posed by the ongoing pandemic. Looking ahead, Pfizer Inc. has high hopes for a successful remainder of the fiscal year and beyond. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Pfizer Inc. More…
| Total Revenues | Net Income | Net Margin |
| 77.94k | 21.47k | 31.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pfizer Inc. More…
| Operations | Investing | Financing |
| 29.27k | -15.78k | -14.83k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pfizer Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 197.21k | 101.29k | 16.95 |
Key Ratios Snapshot
Some of the financial key ratios for Pfizer Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 16.6% | 22.0% | 31.1% |
| FCF Margin | ROE | ROA |
| 33.4% | 15.8% | 7.7% |
Analysis
We at GoodWhale conducted an analysis of PFIZER INC‘s wellbeing, and based on our Risk Rating, PFIZER INC is a medium risk investment in terms of financial and business aspects. During our assessment, we detected two risk warnings in their income sheet and balance sheet. To view these warnings, simply register on our website at goodwhale.com. Our technology provides you with all the data you need to make better informed investment decisions. Furthermore, we believe that investing responsibly is key to long-term success, and we are here to help you make the best decisions for your future. More…
Peers
In the pharmaceutical industry, competition is fierce between companies striving to bring innovative new drugs to market. Among the leaders in this industry are Pfizer Inc and its competitors Astellas Pharma Inc, Roche Holding AG, and AstraZeneca PLC. While each company has its own strengths and weaknesses, they all share a commitment to research and development in an effort to stay ahead of the competition.
– Astellas Pharma Inc ($TSE:4503)
Astellas Pharma Inc is a Japanese pharmaceutical company with a market cap of 3.61T as of 2022. The company’s ROE is 6.6%. Astellas Pharma is engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company’s products include ethical drugs, over-the-counter drugs, and generic drugs. Astellas Pharma also has a clinical research division that conducts clinical trials of new drugs.
– Roche Holding AG ($OTCPK:RHHBY)
Roche Holding AG is a multinational pharmaceutical company headquartered in Basel, Switzerland. The company was founded in 1896 by Fritz Hoffmann-La Roche. Roche is the world’s largest biotech company, with products in the areas of pharmaceuticals, diagnostics, and consumer health. The company’s mission is to “improve lives by enabling people to do more, feel better, and live longer.”
Roche Holding AG has a market cap of 270.34B as of 2022, a Return on Equity of 47.83%. The company’s strong market position and financial performance are due to its innovative products and services, which address a broad range of medical needs. Roche is committed to research and development, and has a strong pipeline of new products in development. The company’s focus on customer needs and its ability to bring new products to market quickly have resulted in strong financial performance and shareholder value.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a pharmaceutical company with a market cap of 152.81 billion as of 2022. The company has a return on equity of -0.94%. AstraZeneca PLC is engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and biologic products for the treatment of cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory diseases.
Summary
Pfizer Inc‘s second quarter earnings report showed no growth in both total revenue and net income year-on-year. Despite this, the company continues to demonstrate strong financial fundamentals, with a relatively healthy balance sheet and high profitability. The market reacted positively, with the stock price increasing by 4% following the announcement.
Moreover, the company’s long track record of successful drug launches and robust pipeline of potential new treatments indicate further growth opportunities. Investors looking for a safe and steady long-term investment option should take Pfizer Inc into consideration.
Related Posts
Recent Posts
